MedTrace Logo

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine

NCT05239806 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2022-04-11

No results posted yet for this study

Summary

The objective of study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E as booster compared with Sinopharm inactivated COVID-19 vaccine as booster. The study will also evaluate the immunogenicity and safety of 2-dose vaccinations.

Conditions

Interventions

BIOLOGICAL

SCTV01C

Day 0; intramuscular injection

BIOLOGICAL

SCTV01E

Day 0; intramuscular injection

BIOLOGICAL

Sinopharm inactivated COVID-19 vaccine

Day 0; intramuscular injection

BIOLOGICAL

Comirnaty

Day 0; intramuscular injection

BIOLOGICAL

SCTV01E

Day 180; intramuscular injection

Sponsors & Collaborators

  • Sinocelltech Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2022-08-01
Completion
2023-08-01

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05239806 on ClinicalTrials.gov